Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07305987
PRO-232 in Patients Subjected to Cataract Surgery (PRO-232)
Phase III Clinical Study, to Evaluate the Efficacy and Safety of PRO-232 Ophthalmic Solution on the Ocular Surface of Patients Postoperative to Cataract Surgery by Phacoemulsification.
Sponsor: Laboratorios Sophia S.A de C.V.
Conditions
Cataract Extraction
Interventions
Dexamethasone phosphate Moxifloxacin / Dexamethasone Ophthalmic Solution Moxifloxacin Hydrochloride, Ophthalmic Placebo
Updated 1 time since 2026 Last updated: Dec 18, 2025 Started: Oct 27, 2025 Primary completion: Jun 30, 2026 Completion: Jul 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE3 trial investigates Cataract Extraction and is currently actively recruiting participants. Laboratorios Sophia S.A de C.V. leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Laboratorios Sophia S.A de C.V.
Data source: Laboratorios Sophia S.A de C.V.
For direct contact, visit the study record on ClinicalTrials.gov .